Cite Score:
1.77
ELSEVIER SCOPUS

Pharmacotherapy Of Type 2 Diabetes – The Future

AUTHORS

AP Abhay 1 , * , DM Ravichand 1 , V Seshayamma 1 , P Satish chandran 1

AUTHORS INFORMATION

1 Department of Pharmacology, Osmania Medical College, Hyderabad – 500 095, India

How to Cite: Abhay A, Ravichand D, Seshayamma V, Satish chandran P. Pharmacotherapy Of Type 2 Diabetes – The Future, Int J Endocrinol Metab. 2006 ; 4(3):e94594.

ARTICLE INFORMATION

International Journal of Endocrinology and Metabolism: 4 (3); e94594
Published Online: January 31, 2006
Article Type: Research Article
Received: May 28, 2019
Accepted: January 31, 2006

Crossmark

CHEKING

READ FULL TEXT
Abstract

In the last decade, explosion in therapeutic op-tions for management of type 2 diabetes mellitus (DM) have increased significantly with advances in recombinant DNA technology, molecular bi-ology, clinical chemistry; analogs of insulin have replaced animal insulin, and may displace NPH, regular lente, ultra lente, insulin’s. Analogs such as insulin glargine, insulin lispro, insulin aspart, and insulin glulisine are becoming mainstream therapy for even type 2 DM Besides oral hypo-glycemic agents i.e., sulphonyl ureas, biguanides and thiazolidinediones, newer insulin analogs and non-insulin antidiabetics are in various stages of development. Incretin analogs, amylin analogs, combined P PAR-γ and α agonists, islet-neogenesis gene-associated protein (INGAP) are most prominent amongst these. This review fo-cuses on pramlintide, an amylin analog, GLP-1 agonists and exenatide, an exendin 4 analog re-cently approved for use in type 2 diabetes by US FDA. Newer insulin delivery methods and drugs have also been reviewed.

Keywords

Pharmacotherapy Diabetes Insulin

© 2006, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

This part is available in the PDF file.

References

  • 1. The references are available in the PDF file.
  • COMMENTS

    LEAVE A COMMENT HERE: